Biologics leader scales rapidly across two strategic sites in Ireland

Founded by physician-scientists in New York 1988, Regeneron is a leading science and technology company delivering life-transforming treatments for serious diseases. The company has nine FDA-approved medicines, eight EMA-approved medicines and numerous product candidates in a range of diseases, including asthma, cancer and infectious diseases. Its revenues in 2022 were over $12 billion and it employs more than 12,000 people worldwide.  
 

Rapid scale in Ireland

In 2013, Regeneron opened its European business office in Dublin and began hiring its first employees there. The same year, it chose Limerick to be the site of its first industrial operations and product supply (IOPS) site outside the United States. The following year, manufacturing commenced at its state-of-the-art facility in Limerick. By the end of 2016, the company had already beaten its initial projected headcount in Ireland with the hiring of its 350th employee. 
 
At the same time, building began on a new quality control labs and process sciences building at the IOPS Limerick site, which in 2017 received a further $100 million investment, with the addition of 300 jobs. By then, the site was the largest bulk biologics production facility in Ireland. 
 
Regeneron also received its first FDA and EMA approvals to manufacture medicine in Ireland for sale in the U.S. and EU. In 2019, construction got underway on a new laboratory and administrative building in Limerick, while a year later, the site reached the milestone of its 1,000th employee in Limerick. Also in 2020, the company announced 400 additional jobs. 
 
The Limerick operation involves high-end specialist jobs in commercial manufacturing, process sciences, quality assurance/control, supply chain as well as various support functions for scientists, chemists and technicians. 
 

How Ireland helps Regeneron 

• Ireland chosen as the company’s first manufacturing facility outside the U.S. 
• Limerick site produces a number of Regeneron’s portfolio of medicines.
• Total investment at its Limerick biologics site exceeds $1 billion.
• Employment at Limerick stands at over 1,400 people.